PRINIVIL Drug Patent Profile

When do Prinivil patents expire, and what generic alternatives are available?

Prinivil is a drug marketed by Merck and is included in one NDA.

The generic ingredient in PRINIVIL is lisinopril. There are twenty-one drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the lisinopril profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Prinivil

A generic version of PRINIVIL was approved as lisinopril by ASCENT PHARMS INC on July 1^st, 2002.

Summary for PRINIVIL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	12
Drug Prices:	Drug price information for PRINIVIL
What excipients (inactive ingredients) are in PRINIVIL?	PRINIVIL excipients list
DailyMed Link:	PRINIVIL at DailyMed

See drug prices for PRINIVIL

Recent Clinical Trials for PRINIVIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
St. Jude Children's Research Hospital	Phase 2
Memorial Health University Medical Center	Phase 1
Centre Hospitalier Universitaire de Saint Etienne	Phase 4

See all PRINIVIL clinical trials

US Patents and Regulatory Information for PRINIVIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-006	Jan 28, 1994		DISCN	No	No
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-003	Dec 29, 1987		DISCN	No	No
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-001	Dec 29, 1987		DISCN	No	No

Expired US Patents for PRINIVIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-006	Jan 28, 1994
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-003	Dec 29, 1987
Merck	PRINIVIL	lisinopril	TABLET;ORAL	019558-004	Oct 25, 1988

International Patents for PRINIVIL

See the table below for patents covering PRINIVIL around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H02131430	AMINO ACID DERIVATIVE AS ANTIHYPERTENSIVE AGENT
Yugoslavia	43532
Bulgaria	38787	METHOD FOR PREPARING CARBOXYALKYL DIPEPTIDES

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: PRINIVIL

Last updated: July 29, 2025

---

Introduction

PRINIVIL, known generically as lisinopril, is an angiotensin-converting enzyme (ACE) inhibitor predominantly prescribed for hypertension, heart failure, and certain renal conditions. Since its introduction, PRINIVIL has become a staple in cardiovascular therapeutics, with significant implications for market dynamics and revenue generation within the pharmaceutical landscape. Understanding its current market trajectory involves analyzing historical performance, competitive positioning, regulatory influences, and emerging trends.

---

Historical Market Context and Current Position

Lisinopril was FDA-approved in 1987, rapidly establishing itself as a frontline agent for hypertension management [1]. Its efficacy, safety profile, and affordability contributed to broad adoption globally. As of 2022, PRINIVIL remains a top-selling ACE inhibitor, with annual revenues estimated in the hundreds of millions USD (specific figures vary by region and manufacturer) [2].

The drug's generic availability bolstered its market penetration, making it accessible across diverse demographics. The expiration of patent protections and different formulation approvals catalyzed a surge in generic competition, intensifying price competition and shifting revenue streams.

---

Market Dynamics

1. Patent Expiry and Generic Competition

The original patent for lisinopril expired in the early 2010s in various markets, precipitating a proliferation of generic manufacturers. This increased market supply resulted in significant price erosion but expanded access. Despite declining average selling prices, overall sales volume expands, partly offsetting revenue diminishment from per-unit price declines.

However, patent litigations and regulatory delays can sometimes temporarily sustain branded drug sales. The primary branded product, such as PRINIVIL (by Pfizer), saw sales decline consistent with generics’ entry but maintained a segment of the market through hospital supplies and specific formulations.

2. Prescribing Trends and Clinical Guidelines

Over time, clinical guidelines influence prescribing behaviors. While ACE inhibitors like lisinopril remain standard, newer drug classes—such as angiotensin receptor blockers (ARBs) and direct-acting vasodilators—offer alternative options, impacting demand.

Nevertheless, ACE inhibitors’ cost-effectiveness sustains their prominence in resource-limited settings and in combination therapy regimes, bolstering their long-term market presence.

3. Regulatory and Price Pressures

Regulatory scrutiny relating to side effects such as cough and angioedema influences prescribing patterns. Additionally, pricing pressures from national health systems and insurance providers aim to curtail costs, compelling manufacturers to innovate or diversify their portfolio.

Pharmaceutical companies, including Pfizer, leverage volume sales and drug repurposing strategies to sustain revenues. Reimbursement policies in key markets (e.g., US, EU, China) directly impact sales trajectories.

4. Emerging Market Penetration

Expanding healthcare infrastructure in emerging economies like India, Brazil, and Southeast Asia fosters growth. Governments’ increasing efforts towards universal healthcare coverage support the expanded use of affordable generics, positioning lisinopril favorably in these markets.

---

Financial Trajectory

1. Revenue Trends and Forecasts

Following patent expiry, global revenues for lisinopril have exhibited a declining trend for the branded product but have been compensated somewhat by rising sales of generics. Industry analysts project a compound annual growth rate (CAGR) of approximately -2% to -3% from 2021-2026 for branded lisinopril [3]. However, the overall ACE inhibitor market—including generics—is expected to grow modestly, driven by aging populations and increasing hypertension prevalence.

2. Investment and R&D

Pharmaceutical companies diversify their ACE inhibitor portfolios through R&D investments, exploring extended-release formulations, fixed-dose combinations, and novel delivery mechanisms to enhance patient adherence and therapeutic effectiveness.

Patent challenges and exclusivity periods influence revenue stability; companies often seek regulatory exclusivities or supply agreements to secure market share. For example, Pfizer's PRINIVIL faced generic competition post-patent expiration, leading to a strategic shift toward biosimilar development and pipeline expansion.

3. Strategic Market Positioning

The industry’s focus includes consolidating market share via partnerships, licensing, and expanding into developing markets. Moreover, mergers and acquisitions aim to optimize distribution channels and bolster generic portfolios—key factors influencing lisinopril's financial landscape.

---

Future Outlook

The long-term outlook for PRINIVIL and lisinopril broadly hinges on several variables:

• Regulatory landscape: Stricter safety pharmacovigilance could influence approval renewal and labeling.
• Market competition: Introduction of novel antihypertensive agents with superior efficacy or tolerability could erode demand.
• Patient adherence: Fixed-dose combinations and once-daily formulations may support sustained market relevance.
• Emerging therapeutics: Advances such as neprilysin inhibitors and SGLT2 inhibitors for cardiovascular and renal diseases may alter prescribing paradigms.

In conclusion, the market dynamics for PRINIVIL have transitioned toward a mature phase characterized by volume-driven revenue despite overarching price pressures. Strategic adaptation by manufacturers and healthcare systems will be pivotal in shaping its ongoing financial trajectory.

---

Key Takeaways

• Patent expiration led to a surge in generic lisinopril availability, significantly impacting branded sales and fostering price competition.
• Prescription patterns continue to favor lisinopril in resource-constrained settings and certain clinical scenarios, sustaining its market presence.
• Regulatory and safety considerations influence future sales; increased vigilance may affect prescribing behavior.
• Emerging markets offer substantial growth opportunities, driven by expanding healthcare access.
• Innovative formulations and combination therapies hold potential to extend lisinopril’s relevance amid competition from newer agents.

---

FAQs

1. What factors most influence lisinopril’s market share today?
Pricing, clinical guideline recommendations, safety profile, availability of generics, and emerging competing therapies primarily determine market share.

2. Are there new formulations or combinations of PRINIVIL under development?
Although most development has focused on generics and biosimilars, fixed-dose combinations with other antihypertensives are common to improve adherence, but no novel PRINIVIL-specific formulations are prominently under development.

3. How do regulatory agencies impact lisinopril’s market trajectory?
Regulatory agencies enforce safety standards, control approvals for new formulations, and influence labeling. Safety signals may lead to label changes or usage restrictions, affecting sales.

4. What are the key regions for lisinopril’s future growth?
Emerging economies in Asia, Latin America, and Africa represent significant growth fronts due to expanding healthcare access and affordability of generics.

5. What should investors consider when evaluating lisinopril-related assets?
Assess patent status, regional regulatory environments, competitive landscape, availability of biosimilars, and the strategic positioning of manufacturing and distribution assets.

---

Sources:

[1] FDA Drug Database, 1987. "Lisinopril", Retrieved from FDA archives.
[2] IQVIA, "Global Cardiovascular Market Report," 2022.
[3] MarketWatch, "ACE inhibitors market outlook," 2022.